Related Experiment Video
Updated: Aug 5, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Biomarkers as surrogates for cancer development
E Hawk1, J L Viner, J A Lawrence
1DCP/GI and Other Cancer Research Group, National Cancer Institute, EPN, Suite 201, 6130 Executive Boulevard, Bethesda, MD 20892-7322, USA. hawke@mail.nih.gov
Abstract:
Biomarkers are routinely applied in the management of chronic diseases to reduce morbidity and mortality through early diagnosis, as well as to assess the necessity for, and responsiveness to, applied interventions. Biomarkers yield mechanistic insights into layers of biologic organization from molecule to organelle, to cell, and finally to cellular organization and tissue. A step-wise approach to the development of tissue-based biomarkers is presented. These biomarkers may serve as molecular targets for scientific inquiry and intervention, as well as approvable endpoints for clinical trials.
